Anticholinergic drugs, which primarily block muscarinic receptors, have a wide range of effects across multiple organ systems. Their clinical pharmacology is determined by the blockade of parasympathetic input, leading to effects that are useful in specific therapeutic settings but can also result in a number of side effects. The degree of response to anticholinergics largely depends on the baseline vagal tone of the individual, with greater effects observed in situations where vagal tone is high. Below is a detailed discussion of their pharmacological actions across different organ systems.
Cardiovascular Effects
The primary cardiovascular action of anticholinergic drugs is the blockade of muscarinic receptors in the sinoatrial node, which leads to tachycardia. This effect is especially beneficial in reversing bradycardia that results from excessive vagal stimulation, such as that seen in the oculocardiac reflex, baroreceptor reflex, or during peritoneal traction in surgery. Anticholinergics like atropine can rapidly increase heart rate by preventing the vagal inhibition of pacemaker activity. However, small doses of atropine (<0.4 mg) have been reported to cause a paradoxical bradycardia, the exact mechanism of which remains unclear.
Additionally, anticholinergics promote conduction through the atrioventricular (AV) node, shortening the P-R interval on the electrocardiogram and reversing vagally mediated heart block. These agents, however, generally have little to no effect on ventricular function or the peripheral vasculature, as cholinergic innervation in these regions is sparse. In some cases, large doses of anticholinergics can cause cutaneous vasodilation, known as the "atropine flush," which is likely a compensatory mechanism to dissipate heat due to the inhibition of sweating.
Respiratory Effects
Anticholinergics have significant effects on the respiratory system, where they inhibit secretions from the nasal passages, trachea, and bronchi. This makes them valuable in surgical or endoscopic procedures involving the airway, as reduced secretions help maintain a clear airway and reduce the risk of aspiration. Anticholinergic drugs also cause bronchodilation by relaxing the smooth muscles of the bronchi, which leads to reduced airway resistance and increased anatomic dead space. This effect is particularly beneficial in patients with chronic obstructive pulmonary disease (COPD) or asthma, where anticholinergic bronchodilators such as ipratropium are commonly used to improve airflow and reduce bronchospasm.
Central Nervous System (CNS) Effects
The effects of anticholinergic drugs on the CNS vary depending on the specific agent and the dosage used. Scopolamine, for example, readily crosses the blood-brain barrier and causes CNS depression, leading to sedation and amnesia. This makes scopolamine useful in certain clinical situations, such as for the prevention of motion sickness and as an adjunct to anesthesia. Conversely, other anticholinergics can cause CNS stimulation, resulting in restlessness, hallucinations, or even delirium, especially at higher doses. These excitatory effects are particularly prominent in elderly patients or those with preexisting cognitive impairment. In cases of severe CNS anticholinergic toxicity, physostigmine, a cholinesterase inhibitor that crosses the blood-brain barrier, can be administered to reverse these effects by increasing acetylcholine levels in the brain.
Gastrointestinal Effects
Anticholinergic drugs have profound effects on the gastrointestinal (GI) system. They markedly reduce salivary secretions, leading to dry mouth (xerostomia), and they also decrease gastric acid secretion, although higher doses are typically required for this effect. By inhibiting parasympathetic stimulation of the GI smooth muscle, anticholinergics slow down intestinal motility and peristalsis, resulting in prolonged gastric emptying time and a risk of constipation. This decreased motility can contribute to gastric stasis and worsen symptoms in patients with conditions such as gastroesophageal reflux disease (GERD). While anticholinergics reduce secretions, they do not prevent aspiration pneumonia, as the effects on esophageal and respiratory protective reflexes remain limited.
Ophthalmic Effects
Anticholinergics, when used systemically or applied topically to the eyes, produce characteristic ophthalmic effects. They cause mydriasis (pupil dilation) and cycloplegia (loss of the ability to accommodate), which results in blurred vision, particularly when focusing on near objects. These effects are a result of blocking the M3 receptors in the iris sphincter and ciliary muscles. While these drugs are used therapeutically in ophthalmology to facilitate retinal examinations and treat certain eye conditions, they can also precipitate acute angle-closure glaucoma in susceptible individuals, especially in patients with pre-existing narrow-angle glaucoma.
Genitourinary Effects
In the genitourinary system, anticholinergics reduce smooth muscle tone in the bladder and ureters, leading to urinary retention. This is particularly problematic for older men with prostatic hypertrophy, who may already have difficulty with urination. By inhibiting M3 receptors in the detrusor muscle, these drugs impair the bladder's ability to contract, which can lead to incomplete emptying and increase the risk of urinary tract infections (UTIs).
Thermoregulatory Effects
Anticholinergic drugs also interfere with the body’s ability to regulate temperature through their effects on sweat glands. By blocking acetylcholine at the M3 receptors in the sweat glands, anticholinergics reduce sweating, which can lead to hyperthermia in hot environments or during physical exertion. This condition is sometimes referred to as atropine fever, and it is most dangerous in infants and the elderly, who are less able to compensate for increased body heat. The inability to sweat and cool down can result in heat stroke if not properly managed.
